Brief: Prokidney - Announced An Update On Its Regen-007 Phase 2 Clinical Study Of React

Prokidney

07/06/2022 13:54

June 7 (Reuters) - Social Capital Suvretta Holdings Corp III
 DNAC.O :
    * PROKIDNEY - ANNOUNCED AN UPDATE ON ITS REGEN-007 PHASE 2
CLINICAL STUDY OF REACT
    * PROKIDNEY- BASED ON OBSERVED FAVORABLE SAFETY PROFILE IN
REGEN-007, PROCEEDING WITH INJECTION OF REACT INTO BOTH KIDNEYS
    * PROKIDNEY- POTENTIAL TO REPORT DATA FROM ENHANCED DELIVERY
APPROACH 1Q 2023

Source text for Eikon:  ID:nGNX83wVFC 
Further company coverage:  DNAC.O 

 ((Reuters.Briefs@thomsonreuters.com;))